Royalty Pharma acquires royalty stake in AstraZeneca drug By Investing.com
Royalty Pharma (RPRX) said it will buy Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront. The deal grants RPRX a 3% to 4% royalty on worldwide net sales, with additional payments tied to milestones. Cliramitug is in Phase 3, with results expected in 2028.
How this was made
The 30-second read
Why it matters
RPRX’s new royalty stake creates incremental, milestone- and outcome-dependent revenue exposure, with near-term cash outlay ($125M upfront) and later tranches tied to 2027 milestones and 2028 trial results.
Market read
Traders can reassess RPRX’s forward royalty revenue profile and risk weighting based on the disclosed royalty rate, upfront funding, and milestone structure.
What to watch
Royalty rate is a range (3% to 4%), and milestone payments depend on clinical and regulatory achievements, so cash-flow timing and realized economics could diverge from headline totals.
Background
Royalty Pharma is acquiring a portion of Neurimmune’s royalty interest tied to AstraZeneca’s Phase 3 antibody cliramitug for ATTR-CM.
Ticker impact
Royalty Pharma will pay Neurimmune up to $425M for a 3% to 4% royalty on AstraZeneca’s cliramitug worldwide net sales.
Likely modest positive bias as investors price in additional royalty revenue potential, tempered by Phase 3 execution risk into 2028.
The article discloses deal economics (upfront $125M, total $425M, 3% to 4% royalty, milestone tranches) but no immediate clinical/regulatory readout; valuation impact depends on probability-weighting DepleTTR-CM outcomes.
Market effects
Highlights continued monetization of late-stage biotech assets via royalty structures, supporting sentiment for royalty/biopharma finance models.
Primarily US-listed biotech/royalty investor sentiment; limited direct regional spillover beyond healthcare investors.
Royalty exposure is tied to AstraZeneca’s global net sales, linking US royalty demand to EU pharma pipeline value.
Counterpoint
Royalty economics may be less supportive if cliramitug’s Phase 3 probability of success is low or if net sales ramp is slower than implied by the peak sales target.
Key entities
- companyRoyalty Pharma plc
Acquiring a portion of Neurimmune’s royalty interest in cliramitug for up to $425M.
- companyAstraZeneca
Holds the cliramitug program; provides a peak sales target of $3B to $5B at its May 2024 Investor Day.
- companyNeurimmune
Holds the original royalty interest being partially acquired by Royalty Pharma.
- drugcliramitug
Phase 3 antibody in DepleTTR-CM trial for ATTR-CM; results expected in 2028.
